Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Pozdnyakova O, Wu K, Patki A, et al. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. Mod Pathol. 2014;27(11):1447–54.
2. Pardanani A, Vannucchi AM, Passamonti F, et al. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia. 2011;25(2):218–25.
3. Keohane C, Kordasti S, Seidl T, et al. JAK inhibition induces silencing of T helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol. 2015;171(1):60–73.
4. Celgene Corporation. INREBIC® (fedratinib) capsules, for oral use: US prescribing information. 2019.
http://www.fda.gov/
. Accessed 16 Aug 2019.
5. Celgene Corporation. U.S. FDA approves INREBIC® (fedratinib) as first new treatment in nearly a decade for patients with myelofibrosis [media release]; 16 Aug 2019.
http://ir.celgene.com
.
Cited by
90 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献